Heart-on-a-Chip Technology Predicts Preclinical Systolic and Diastolic in vivo Observations for Novel Cardiac Drug in Development
November 18, 2019
News
NEW YORK, NY (Newswire.com)— TARA Biosystems, Inc. today reported in vivo and in vitro functional data from a study of investigational candidate, MYK-491, …
TARA Biosystems Launches Cardiotype.Ca™ Cardiac Calcium Signaling Assay: In Vitro Assay Accelerates Drug Development in Human-Relevant Heart Models
September 23, 2019
News
NEW YORK, NY (Newswire.com) - TARA Biosystems, Inc. launched Cardiotype.Ca™, its in vitro system for assessing cardiac calcium signaling. The new assay can be used independently or in combination with TARA’s <…
Heart-on-a-Chip Mimics Drug Response Seen in Humans: In Vitro Approach Provides Predictive Platform for Human-Based Drug Discovery
August 6, 2019
News
NEW YORK, N.Y. (Newswire.com)— Researchers from TARA Biosystems, Inc. and GlaxoSmithKline (GSK) today published data demonstrating that TARA’s engineered heart-on-a-chip system replicated drug responses found in adult humans. The …
TARA Secures Exclusive Worldwide License to Columbia University Intellectual Property relating to Engineered Human Cardiac Tissues
May 28, 2019
News
NEW YORK, N.Y. (Newswire.com)— TARA Biosystems, Inc. (TARA), a company offering physiologically relevant human “heart-on-a-chip” tissue models for cardiac risk assessment and drug discovery applications, today announced the execution of an exclusive worldwide license agreement with Columbia …
TARA Announces Issuance of US Patent for Biowire™ II Platform
May 14, 2019
News
New York, NY, (Newswire.com) - TARA Biosystems, Inc. (TARA), a company offering physiologically relevant human “heart-on-a-chip” tissue models for cardiac risk assessment and drug discovery applications, today announced that the United States Patent and Trademark Office (USPTO) has …
TARA Biosystems Biowire™ II Heart-on-a-Chip Platform Published in CELL
January 24, 2019
News
NEW YORK, (Newswire.com) TARA Biosystems, Inc., a company offering physiologically relevant human “heart-on-a-chip” tissue models for cardiac risk assessment and drug discovery applications, today announced the first peer-reviewed publication of its Biowire™ II platform by a team of …
TARA Biosystems and Insilico Medicine Announce Drug Discovery Collaboration for Cardiac Disease
January 7, 2019
Featured
New York – TARA Biosystems, Inc. a company offering “heart-on-a-chip” tissue models for drug discovery and risk assessment applications and Insilico Medicine, an artificial intelligence company developing end-to-end drug discovery pipelines for age-related diseases, announced today the launch of a collaboration to discover and develop novel therapies for …
TARA Launches Cardiotype.Fo, Best-In-Class Assay for Cardiac Contractility
September 27, 2018
News
New York, (Newswire.com) - TARA Biosystems, Inc. a company offering “heart-on-a-chip” tissue models for drug discovery and development applications announced today the launch of Cardiotype.Fo, the best-in-class in vitro system for assessment of cardiac …
TARA CEO Misti Ushio Named to Fast Company's 100 Most Creative People in Business
May 30, 2018
Press Releases
New York, (Newswire.com) - TARA Biosystems is proud to announce that TARA CEO Dr. Misti Ushio has been recognized by Fast Company as one of the Top 100 Most Creative People in Business today. The annual list honors an …
TARA Appoints Donna See as Chief Business Officer
May 16, 2018
Press Releases
New York, (Newswire.com) – TARA Biosystems, Inc., a company offering physiologically human relevant “heart-on-a-chip” tissue models for drug discovery and development applications, announced the appointment of Donna See as Chief Business Officer. In this newly created role, Donna will …